Verastem Inc Asset Resilience Ratio
Verastem Inc asset resilience ratio. Verastem Inc (VSTM) has an Asset Resilience Ratio of 7.08% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See VSTM defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Verastem Inc (2011–2025)
Asset resilience ratio of Verastem Inc from 2011 to 2025. This chart shows how Verastem Inc's Asset Resilience Ratio has changed over time. Read total liabilities of Verastem Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Verastem Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Verastem Inc's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $16.13 Million | 7.08% |
| Total Liquid Assets | $16.13 Million | 7.08% |
Asset Resilience Insights
- Limited Liquidity: Verastem Inc maintains only 7.08% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Verastem Inc Industry Peers by Asset Resilience Ratio
Compare Verastem Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Verastem Inc Asset Resilience Ratio by Year (2011–2025)
Verastem Inc asset resilience ratio by year from 2011 to 2025. The table below shows the annual Asset Resilience Ratio data for Verastem Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 3.58% | $8.81 Million | $246.44 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $101.54 Million | -- |
| 2023-12-31 | 39.55% | $59.22 Million | $149.72 Million | +25.92pp |
| 2022-12-31 | 13.64% | $12.96 Million | $95.05 Million | -59.07pp |
| 2021-12-31 | 72.71% | $79.00 Million | $108.66 Million | +25.12pp |
| 2020-12-31 | 47.58% | $73.44 Million | $154.35 Million | +25.53pp |
| 2019-12-31 | 22.06% | $31.99 Million | $145.05 Million | -21.15pp |
| 2018-12-31 | 43.21% | $119.79 Million | $277.24 Million | +38.20pp |
| 2017-12-31 | 5.01% | $4.50 Million | $89.79 Million | -53.04pp |
| 2016-12-31 | 58.05% | $48.55 Million | $83.63 Million | -17.45pp |
| 2015-12-31 | 75.50% | $85.39 Million | $113.09 Million | +15.92pp |
| 2014-12-31 | 59.58% | $58.77 Million | $98.65 Million | -6.22pp |
| 2013-12-31 | 65.80% | $82.42 Million | $125.26 Million | +15.78pp |
| 2012-12-31 | 50.02% | $46.48 Million | $92.92 Million | +4.53pp |
| 2011-12-31 | 45.49% | $26.86 Million | $59.04 Million | -- |
About Verastem Inc
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAP… Read more